ADB116 for injection receives approval for clinical trial
October 27, 2025
Source: drugdu
103
October 24, Aidi Pharmaceuticals(688488.SH) announced that the company and its controlling subsidiary, Nanjing Nanda Pharmaceutical Co., Ltd., have received the "Notice of Approval for Clinical Trial of a Drug" from the National Medical Products Administration (NMPA), authorizing the company to conduct clinical trials of its investigational Class 2 chemically modified new drug, ADB116 for injection. This drug is intended for thrombolytic therapy in patients with acute ischemic stroke. If successfully approved for marketing in the future, it will provide more treatment options for stroke patients and further enhance the company's core competitiveness and development potential. However, it should be noted that after receiving the Notice of Approval for Clinical Trial of a Drug, the drug must undergo clinical trials to obtain efficacy and safety data, and must undergo review and approval by the NMPA before it can be manufactured and marketed.
Source：https://finance.eastmoney.com/a/202510243543623696.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
